The Mutual Recognition Procedure (MRP) is a European marketing authorisation pathway for a medicinal product that has already received national authorisation in at least one Member State. The applicant applies in additional states for recognition of the existing scientific assessment and the authorisation granted by the Reference Member State. Upon successful completion, the other involved states each issue a national marketing authorisation.
Initial Authorisation as the Basis
The Mutual Recognition Procedure, often referred to as MRP, builds upon an existing national marketing authorisation. The Member State that has already authorised the medicinal product assumes the role of the Reference Member State. It transmits its assessment of the product to the states where additional authorisation is sought. These states are referred to as Concerned Member States.
The Concerned Member States review the assessment report and the product information associated with the authorisation. They are requested to recognise the authorisation of the Reference Member State but retain their national jurisdiction for the final decision. If coordination is successful, each Concerned Member State issues its own national authorisation. Thus, the MRP leads to a mutually recognised product, not a single centralised authorisation from the European Commission.
The existing authorisation must form the factual basis for the application in the additional states. Therefore, an up-to-date and consistent dossier, the assessment report, and consistent information regarding quality, safety, efficacy, summary of product characteristics, labelling, and package leaflet are crucial. Queries from the Concerned Member States may necessitate an update or clarification of these documents.
Roles and Coordination Among Member States
In the MRP, the Reference Member State assumes a special scientific and coordinating function. It provides its assessment, explains it in discussions with the Concerned Member States, and acts as the central interface. The Concerned Member States assess whether they can accept the evaluation and the proposed product information. Agreement does not mean that the national authority relinquishes its responsibility, but rather that it adopts the coordinated assessment as the basis for its decision.
In case of objections, the scientific justification is critical. Unresolved disagreements can be referred to the relevant coordination procedure. For project planning, this means that the regulatory strategy must consider not only the original authorisation status but also the data status, any variations to the authorisation, and country-specific product information. An already granted national authorisation is not a substitute for preparing the recognition phase.
Distinction from Decentralised and Centralised Procedures
The difference from the Decentralised Procedure lies in the starting point. For the MRP, the medicinal product must already be nationally authorised in at least one Member State. The DCP, in contrast, is intended for a medicinal product not yet authorised in any Member State; there, the initial assessment occurs in parallel for all participating states. However, both pathways utilise the roles of Reference Member State and Concerned Member State.
The MRP also fundamentally differs from the Centralised Procedure. In the Centralised Procedure, the EMA assesses the application, and the European Commission grants a single authorisation valid throughout the Union. In the MRP, authorisations remain national decisions by the involved authorities. A medicinal product falling under the mandatory scope of the Centralised Procedure cannot be authorised via the MRP.
The choice of procedure should therefore not depend solely on the number of target markets. Crucial factors also include whether a viable national initial authorisation exists, whether its dossier is up-to-date, and whether the medicinal product is eligible for the centralised route. While the MRP reuses existing assessment results, it does not exempt from thorough regulatory and scientific preparation for the additional states.
Relevance for clinical trials
Clinical data supporting a national initial authorisation must remain complete, current, and plausible for recognition in additional states. This includes a comprehensible efficacy analysis, a consistent safety assessment, and a dossier that reflects findings that have emerged between the original authorisation and the MRP. Differing expectations for translations, local product information, or administrative documents cannot replace clinical evidence but must be consistently linked with it.
Full-service CROs like Mediconomics support the evaluation and consolidation of clinical data, pharmacovigilance, medical writing, and regulatory documentation. They can also facilitate the cross-country coordination of study documents, product information, and responses to regulatory authority queries to ensure that existing evidence is presented uniformly across all target markets.
Frequently Asked Questions (FAQ)
What authorisation must exist before an MRP?
The medicinal product must already be nationally authorised in at least one Member State.
What is the outcome of an MRP?
If successful, the Reference Member State and the Concerned Member States issue national marketing authorisations based on a harmonised assessment.
Can the MRP replace a centralised authorisation?
No. For medicinal products within the mandatory scope of the Centralised Procedure, this EU-wide pathway is decisive.
Regulatory References
- Directive 2001/83/EC, Articles 27 to 39 — contains the basis for recognition and coordination.
- HMA, Medicines Approval System — explains the MRP and its prerequisite of an existing national authorisation.
- CMDh, General Info — refers to procedural guidelines and the role of the Reference Member State.